- Home
- HOWL vs RDI Comparison
HOWL vs RDI Comparison
Compare HOWL & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | RDI |
|---|---|---|
| Founded | 2017 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 24.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HOWL | RDI |
|---|---|---|
| Price | $0.65 | $1.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 350.1K | 23.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.00 |
| 52 Week High | $2.23 | $1.65 |
Technical Indicators
Market Signals| Indicator | HOWL | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 42.65 |
| Support Level | $0.57 | $1.00 |
| Resistance Level | $0.67 | $1.16 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 35.61 | 25.00 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.